10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RBPMS Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP20354b

Product Information

Application	WB, E
Primary Accession	Q93062
Other Accession	Q9WVB0
Reactivity	Human
Predicted	Mouse, Rat, Bovine, Canine, Rabbit, Chicken
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB42810
Calculated MW	21802
Antigen Region	166-193

Additional Information

Gene ID	11030
Other Names	RNA-binding protein with multiple splicing, RBP-MS, Heart and RRM expressed sequence, Hermes, RBPMS, HERMES
Target/Specificity	This RBPMS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-193 amino acids from the C-terminal region of human RBPMS.
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	RBPMS Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information


Name	RBPMS (HGNC:19097)
Synonyms	HERMES

Function	[Isoform A]: RNA binding protein that mediates the regulation of pre-mRNA alternative splicing (AS) (PubMed:24860013, PubMed:26347403). Acts either as activator (FLNB, HSPG2, LIPA1, MYOCD, PTPRF and PPFIBP1) or repressor (TPM1, ACTN1, ITGA7, PIEZO1, LSM14B, MBNL1 and MBML2) of splicing events on specific pre-mRNA targets (By similarity). Together with RNA binding proteins RBFOX2 and MBNL1/2, activates a splicing program associated with differentiated contractile vascular smooth muscle cells (SMC) by regulating AS of numerous pre- mRNA involved in actin cytoskeleton and focal adhesion machineries, suggesting a role in promoting a cell differentiated state (By similarity). Binds to introns, exons and 3'-UTR associated with tandem CAC trinucleotide motifs separated by a variable spacer region, at a minimum as a dimer. The minimal length of RNA required for RBPMS- binding tandem CAC motifs is 15 nt, with spacing ranging from 1 to 9 nt. Can also bind to CA dinucleotide repeats (PubMed:24860013, PubMed:26347403). Mediates repression of TPM1 exon 3 by binding to CAC tandem repeats in the flanking intronic regions, followed by higher- order oligomerization and heterotypic interactions with other splicing regulators including MBNL1 and RBFOX2, which prevents assembly of ATP- dependent splicing complexes (By similarity).
Cellular Location	Nucleus. Cytoplasm. Cytoplasm, Stress granule. Cytoplasm, P-body. Note=Localized to cytoplasmic stress granules after oxidative stress (PubMed:24860013). Translocates into cytoplasmic stress granules that probably corresponds to P-bodies in response to oxidative stress (PubMed:26347403)
Tissue Location	Ubiquitously expressed, at various levels depending on the isoform and the tissue (PubMed:8855282). Strongly expressed in the heart, prostate, small intestine, large intestine, and ovary; moderately expressed in the placenta, lung, liver, kidney, pancreas, and testis; and poorly expressed in the skeletal muscle, spleen, thymus and peripheral leukocytes (PubMed:8855282)

Background

Acts as a coactivator of transcriptional activity. Required to increase TGFB1/Smad-mediated transactivation. Acts through SMAD2, SMAD3 and SMAD4 to increase transcriptional activity. Increases phosphorylation of SMAD2 and SMAD3 on their C-terminal SSXS motif, possibly through recruitment of TGFBR1. Promotes the nuclear accumulation of SMAD2, SMAD3 and SMAD4 proteins. Binds to poly(A) RNA.

Images



RBPMS Antibody (C-term) (Cat. #AP20354b) western blot analysis in NCI-H460 cell line lysates (35ug/lane).This demonstrates the RBPMS antibody detected the RBPMS protein (arrow).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.